GlassScriptPhysician profile
Meena S George
NPI 1982913661
$28,034.64
in general payments reported to CMS, 2019-2025
26 companies · $12K in 2025
The $12K reported for 2025 was more than what 96% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,794 · 2020: $4,964 · 2021: $99.24 · 2022: $501 · 2023: $609 · 2024: $3,356 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Food and Beverage: $3,323 · Travel and Lodging: $675.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,679.00 |
| Food and Beverage | $3,323.08 |
| Travel and Lodging | $674.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $13,546.45 | 2019-2025 | Vabysmo |
| Allergan, INC. | $6,606.79 | 2019-2021 | |
| Astellas Pharma US INC | $2,348.57 | 2023-2025 | Izervay |
| Cardinal Health 108 LLC | $1,575.00 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $751.64 | 2019-2025 | Eylea Hd, Eylea |
| Genentech, INC. | $730.00 | 2025 | Susvimo, Vabysmo |
| Abbvie INC. | $437.13 | 2022-2025 | |
| Apellis Pharmaceuticals, INC. | $432.90 | 2023-2025 | Syfovre |
| Eyepoint US, INC. | $392.11 | 2022-2024 | |
| Harrow Eye, LLC | $292.36 | 2024-2025 | Iheezo, Triesence |
| Alimera Sciences, INC. | $179.91 | 2023-2024 | Iluvien, Yutiq |
| Coherus Oncology, INC. | $130.16 | 2023-2024 | |
| Bausch & Lomb Americas INC. | $105.72 | 2022-2025 | Xipere |
| Biogen, INC. | $93.40 | 2022-2024 | Byooviz |
| Amgen INC. | $88.73 | 2024-2025 | Tepezza |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $53.23 | 2024 | Dextenza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $48.96 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $39.51 | 2025 | Purified Cortrophin Gel, Iluvien |
| Horizon Therapeutics Plc | $35.90 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $34.36 | 2020-2025 | Acthar |
| Boston Scientific Corporation | $30.20 | 2023 | Advantage System |
| Sandoz INC. | $23.53 | 2024 | Cimerli |
| Amphastar Pharmaceuticals, INC. | $18.72 | 2024 | |
| Novartis Pharmaceuticals Corporation | $14.76 | 2022 | |
| Mallinckrodt Enterprises LLC | $14.15 | 2019 | |
| Optos, INC. | $10.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meena George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.